AU2019225166B2 - Small molecules for inducing selective protein degradation and uses thereof - Google Patents
Small molecules for inducing selective protein degradation and uses thereof Download PDFInfo
- Publication number
- AU2019225166B2 AU2019225166B2 AU2019225166A AU2019225166A AU2019225166B2 AU 2019225166 B2 AU2019225166 B2 AU 2019225166B2 AU 2019225166 A AU2019225166 A AU 2019225166A AU 2019225166 A AU2019225166 A AU 2019225166A AU 2019225166 B2 AU2019225166 B2 AU 2019225166B2
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- alkyl
- certain embodiments
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634679P | 2018-02-23 | 2018-02-23 | |
| US62/634,679 | 2018-02-23 | ||
| PCT/US2019/019180 WO2019165229A1 (en) | 2018-02-23 | 2019-02-22 | Small molecules for inducing selective protein degradation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019225166A1 AU2019225166A1 (en) | 2020-08-06 |
| AU2019225166B2 true AU2019225166B2 (en) | 2024-10-31 |
Family
ID=67687887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019225166A Active AU2019225166B2 (en) | 2018-02-23 | 2019-02-22 | Small molecules for inducing selective protein degradation and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11802132B2 (enExample) |
| EP (1) | EP3755325A4 (enExample) |
| JP (2) | JP7472026B2 (enExample) |
| CN (1) | CN112020358A (enExample) |
| AU (1) | AU2019225166B2 (enExample) |
| CA (1) | CA3090417A1 (enExample) |
| WO (1) | WO2019165229A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10039809B2 (en) | 2013-12-18 | 2018-08-07 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| US10886309B2 (en) | 2015-11-06 | 2021-01-05 | Artilux, Inc. | High-speed light sensing apparatus II |
| US10418407B2 (en) | 2015-11-06 | 2019-09-17 | Artilux, Inc. | High-speed light sensing apparatus III |
| US10254389B2 (en) | 2015-11-06 | 2019-04-09 | Artilux Corporation | High-speed light sensing apparatus |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11105928B2 (en) | 2018-02-23 | 2021-08-31 | Artilux, Inc. | Light-sensing apparatus and light-sensing method thereof |
| US11482553B2 (en) | 2018-02-23 | 2022-10-25 | Artilux, Inc. | Photo-detecting apparatus with subpixels |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| TWI780007B (zh) | 2018-04-08 | 2022-10-01 | 美商光程研創股份有限公司 | 光偵測裝置及其系統 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| CA3103185A1 (en) | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3864030A4 (en) * | 2018-10-12 | 2022-09-21 | The Scripps Research Institute | Compounds and methods for dcaf-mediated protein degradation |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| KR102980990B1 (ko) | 2019-04-05 | 2026-06-25 | 카이메라 쎄라퓨틱스 인코포레이티드 | Stat 분해제 및 이의 용도 |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| EP4069726A4 (en) | 2019-12-04 | 2024-03-20 | The Scripps Research Institute | GLP2 RECEPTOR AGONISTS AND METHOD OF USE |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP7871189B2 (ja) * | 2019-12-17 | 2026-06-08 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| EP4681715A3 (en) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| US20240024490A1 (en) * | 2021-04-09 | 2024-01-25 | The Broad Institute, Inc. | Bifunctional molecules for selective modification of target substrates |
| EP4323340A2 (en) | 2021-04-13 | 2024-02-21 | President and Fellows of Harvard College | E3 ligase binders and uses thereof |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| BR112023024507A2 (pt) | 2021-05-26 | 2024-02-15 | C4 Therapeutics Inc | Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| US20250129047A1 (en) | 2021-07-04 | 2025-04-24 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| IL316803A (en) | 2022-06-06 | 2025-01-01 | C4 Therapeutics Inc | Bicyclic glutarimide-modified cervalon-binding agents |
| CN122206684A (zh) | 2023-06-30 | 2026-06-12 | 默克专利有限公司 | 用于kras蛋白降解的异双功能化合物 |
| JP2026524477A (ja) | 2023-06-30 | 2026-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｋｒａｓの分解のためのヘテロ二官能性化合物 |
| WO2026107062A1 (en) | 2024-11-13 | 2026-05-21 | Recludix Pharma, Inc. | Stat6 degraders and uses thereof |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106725A1 (en) * | 2013-05-08 | 2016-04-21 | The Johns Hopkins University | Novel bis-Benzylidine Piperidone Proteasome Inhibitor with Anticancer Activity |
| US20160176916A1 (en) * | 2014-12-23 | 2016-06-23 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053245A1 (en) * | 2007-05-29 | 2009-02-26 | Mutz Mitchell W | Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood |
| EP2667196A1 (en) | 2012-05-26 | 2013-11-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bioorthogonal chemical inducers of reversible dimerization for control of protein interactions in cells |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA3000822A1 (en) | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
-
2019
- 2019-02-22 JP JP2020544488A patent/JP7472026B2/ja active Active
- 2019-02-22 US US16/969,772 patent/US11802132B2/en active Active
- 2019-02-22 CA CA3090417A patent/CA3090417A1/en active Pending
- 2019-02-22 CN CN201980027535.9A patent/CN112020358A/zh active Pending
- 2019-02-22 WO PCT/US2019/019180 patent/WO2019165229A1/en not_active Ceased
- 2019-02-22 EP EP19757828.9A patent/EP3755325A4/en active Pending
- 2019-02-22 AU AU2019225166A patent/AU2019225166B2/en active Active
-
2024
- 2024-02-06 JP JP2024016079A patent/JP7820423B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106725A1 (en) * | 2013-05-08 | 2016-04-21 | The Johns Hopkins University | Novel bis-Benzylidine Piperidone Proteasome Inhibitor with Anticancer Activity |
| US20160176916A1 (en) * | 2014-12-23 | 2016-06-23 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021514958A (ja) | 2021-06-17 |
| CN112020358A (zh) | 2020-12-01 |
| US20200407371A1 (en) | 2020-12-31 |
| JP2024054209A (ja) | 2024-04-16 |
| EP3755325A4 (en) | 2022-03-02 |
| JP7472026B2 (ja) | 2024-04-22 |
| EP3755325A1 (en) | 2020-12-30 |
| CA3090417A1 (en) | 2019-08-29 |
| WO2019165229A1 (en) | 2019-08-29 |
| AU2019225166A1 (en) | 2020-08-06 |
| JP7820423B2 (ja) | 2026-02-25 |
| US11802132B2 (en) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7820423B2 (ja) | 選択的なタンパク質分解を誘導するための低分子およびその使用法 | |
| AU2017363313B2 (en) | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | |
| AU2017252460B2 (en) | EZH2 inhibitors and uses thereof | |
| US12187701B2 (en) | Taire family kinase inhibitors and uses thereof | |
| AU2020294169B2 (en) | Acetamide thienotriazolodiazepines and uses thereof | |
| JP7660063B2 (ja) | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 | |
| JP7680999B2 (ja) | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 | |
| AU2019224089B2 (en) | Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof | |
| CA2996974A1 (en) | Cyano thienotriazolodiazepines and uses thereof | |
| US20230117680A1 (en) | Cyclophilin d inhibitors and uses thereof | |
| AU2019318046B2 (en) | Histone demethylase 5 inhibitors and uses thereof | |
| US20250109165A1 (en) | Cyclophilin inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |